Revolution Medicines, Inc. (RVMD) Stock Price & Analysis
Revolution Medicines, Inc. (RVMD) closed at USD 187.69 on Thursday, October 22, 2026, down 3.39% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 194.28; the Oct 22, 2026 session ranged USD 185.34–194.59 on volume of 1,487,129 shares. Market capitalization is $40.23B, with a 52-week range of USD 52.48–224.31 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:08 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RVMD.md
Key facts (RVMD)
- Analysts: Buy (mean 1.84 on a 1–5 scale) (25 analysts), mean target USD 258.84 (range 179–320).
- Total return with dividends: 1Y +251.2% vs S&P 500 +14.9%; 5Y +587.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -2.39, revenue estimate $27.7M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RVMD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $29.4M | $35.4M | $11.6M | $0K | $0K | — |
| Operating income | -$188M | -$258M | -$487M | -$690M | -$1.18B | -$1.63B |
| Net income | -$187M | -$249M | -$436M | -$600M | -$1.13B | -$1.77B |
| EPS (diluted) | -$2.57 | -$3.08 | -$3.86 | -$3.58 | -$5.95 | — |
| Free cash flow | -$154M | -$235M | -$358M | -$568M | -$914M | -$1.23B |
| Operating margin | -639.7% | -730.0% | -4207.1% | — | — | — |
| Net margin | -636.6% | -703.0% | -3768.3% | — | — | — |
| Revenue growth | -31.6% | +20.4% | -67.3% | -100.0% | — | — |
| Cash + short-term investments | $577M | $645M | $1.85B | $2.29B | $2.03B | — |
| Total debt | — | — | — | — | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RVMD)
P/B 15.4x · FCF yield -3.06% · Earnings yield -4.40% · Net cash $3.45B · EV $36.8B
Analysts (RVMD)
Consensus Buy (mean 1.84 on a 1–5 scale), 25 analysts; mean target USD 258.84 (low 179, high 320).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Reiterated | Buy | $250 |
| 2026-10-19 | Truist Securities | Target raised | Buy | $240 → $241 |
| 2026-10-16 | William Blair | Initiated | Outperform | |
| 2026-10-15 | Needham | Reiterated | Buy | $275 |
| 2026-10-14 | RBC Capital | Target raised | Outperform | $259 → $260 |
| 2026-10-08 | RBC Capital | Target raised | Outperform | $251 → $259 |
| 2026-10-07 | Truist Securities | Target raised | Buy | $239 → $240 |
| 2026-09-28 | Brookline Capital | Initiated | Buy | $318 |
| 2026-09-21 | B of A Securities | Target raised | Buy | $225 → $265 |
| 2026-09-10 | Morgan Stanley | Initiated | Overweight | $255 |
| 2026-09-09 | Stifel | Target raised | Buy | $215 → $230 |
| 2026-08-31 | Needham | Target raised | Buy | $240 → $275 |
Total return (dividends reinvested) (RVMD)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +251.2% | +587.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +252.7% | +46.9% |
| Volatility (annualized) | 61.9% | 60.4% |
| Max drawdown | -24.9% (Jan 2026→Mar 2026) | -53.5% (Nov 2021→May 2022) |
RVMD suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Aethon Therapeutics | “In March 2024, we entered into a collaboration agreement with Aethon Therapeutics, Inc. (Aethon) pursuant to which Aethon is conducting research related to use of novel bispecific antibodies to mount an immune attack directed at the cancer cells targeted by” |
| Partner | AMGEN INC (AMGN) | “In February 2025, we entered into a clinical collaboration with Amgen Inc. (Amgen) pursuant to which Amgen is evaluating its compound AMG 193, an MTA-cooperative PRMT5 inhibitor, in combination with daraxonrasib in patients with 2L PDAC as part of an Amgen-sponsored trial.” |
| Partner | Summit Therapeutics Inc. (SMMT) | “In June 2025, we entered into a clinical collaboration with Summit Therapeutics, Inc. (Summit) pursuant to which we are evaluating the safety and efficacy, in multiple solid tumor settings, of our clinical-stage RAS(ON) Inhibitors, including daraxonrasib, elironrasib and zoldonrasib, in combination with Summit's ivonescimab, a PD-1/VEGF bispecific antibody.” |
| Partner | Tango Therapeutics, Inc. (TNGX) | “In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc. (Tango) pursuant to which Tango is evaluating its compound vopimetostat (TNG462), an MTA-cooperative PRMT5 inhibitor, in combination with daraxonrasib or zoldonrasib in patients with MTAP-depleted, RAS mutant PDAC or lung cancer as part of a Tango-sponsored trial.” |
| Partner | EQRx | “To date, we have primarily financed our operations through the sale or issuance of preferred stock and common stock and upfront payments and research and development cost reimbursement received in connection with our prior collaboration with Sanofi and the EQRx Acquisition.” |
| Partner | Cowen and Company | “In November 2021, we entered into a sales agreement with TD Securities (USA) LLC (f/k/a Cowen and Company LLC) (TD Cowen), as amended in March 2024, to sell shares of our common stock, from time to time, with aggregate gross proceeds of up to $250 million, through an at-the-market equity offering program (the 2021 ATM).” |
Quoted from the company's 10-K filed Feb 25, 2026.
Companies that name RVMD in their SEC reports
| Relationship to RVMD | Company | Filing | Sentence |
|---|---|---|---|
| partner | Silexion Therapeutics Corp (SLXN) | 10-K Mar 17, 2026 | “For example, there are an increasing number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS G12V, in a variety of manners and for a variety of indications, including cancer, including Bristol-Myers Squibb Company (through the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration …” |
| customer | Tango Therapeutics, Inc. (TNGX) | 10-K Mar 5, 2026 | “We have entered into separate clinical collaboration and supply agreements with RevMed, Lilly, and Erasca, under which we plan to conduct combination clinical trials with RevMed's RAS(ON) multi- and G12D-selective inhibitors, Lilly's abemaciclib and Erasca's pan-RAS molecular glue, respectively.” |
RVMD company outlook (results filed Aug 5, 2026)
- “Revolution Medicines is updating its full year 2026 GAAP operating expense guidance to a range of $2.1 to $2.2 billion, which includes estimated non-cash stock-based compensation expense of between $270 and $290 million.”
Quoted word-for-word from the SEC 8-K results press release.
RVMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-2.39 | $-1.99 | +20.0% | $27.7M | 21 |
| Next quarter (ends Dec 2026) | $-1.98 | $-1.73 | +14.5% | $167.4M | 21 |
| Current fiscal year (ends Dec 2026) | $-9.58 | $-8.07 | +18.8% | $200.8M | 24 |
| Next fiscal year (ends Dec 2027) | $-5.78 | $-5.80 | -0.3% | $1.31B | 24 |
RVMD options: expected move
Options price a move of about ±14.1% (±$26.60) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±5.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 62.5% | ±14.1% |
| Dec 18, 2026 | 56 | 58.1% | ±18.3% |
| Jan 15, 2027 | 84 | 52.9% | ±20.3% |
| Mar 19, 2027 | 147 | 53.6% | ±26.9% |
| May 21, 2027 | 210 | 54.3% | ±32.5% |
| Jun 17, 2027 | 237 | 53.1% | ±33.7% |
| Aug 20, 2027 | 301 | 53.7% | ±38.2% |
| Nov 19, 2027 | 392 | 53.9% | ±43.5% |
30-day implied volatility 59.5% vs 47.7% realized over the last 30 trading days. Put/call ratio (volume) 0.16. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:08 UTC)
| Price | USD 187.69 |
|---|---|
| Change | ▼ 3.39% (down) |
| Previous Close | USD 194.28 |
| Open | USD 192.06 |
| Day Range | USD 185.34 – 194.59 |
| 52-Week Range | USD 52.48 – 224.31 |
| Volume | 1,487,129 shares |
| Market Cap | $40.23B |
| Exchange | NMS |
Technical Analysis (RVMD)
Nexqual's technical model rates RVMD "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.59 (neutral) |
| vs SMA50 | Below (USD 201.88) |
| MACD | -3.45 (negative) |
Analyst Ratings (RVMD)
Wall Street analysts rate RVMD "Buy" based on 25 analysts, with a mean price target of USD 258.84 (range USD 179–320), per Nexqual as of October 23, 2026 at 10:08 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 258.84 |
| High Target | USD 320 |
| Low Target | USD 179 |
| Buy / Hold / Sell | 24 / 1 / 0 |
Earnings (RVMD)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -2.39 |
| Revenue Estimate | $27.71M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -3.06 vs est -2.06 ▼ miss |
| 2026-03-31 | USD -2.29 vs est -1.84 ▼ miss |
| 2025-12-31 | USD -1.86 vs est -1.56 ▼ miss |
| 2025-09-30 | USD -1.61 vs est -1.41 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Financials & Fundamentals (RVMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -79.09% |
| Debt / Equity | 0.46 |
| Current Ratio | 11.38 |
| Total Cash | $3.94B |
| Total Debt | $1.19B |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Financial Health Score (RVMD)
Nexqual rates Revolution Medicines, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $3.94B cash and investments vs $487M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$898M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -79%, ROA -30.1% |
Ownership (RVMD)
| Insider Ownership | +1.85% |
|---|---|
| Institutional Ownership | +102.34% |
| Shares Outstanding | 214.34M |
| Float | 184.61M |
| Short % of Float | +5.88% |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Leadership (RVMD)
Revolution Medicines, Inc. is led by Mark A. Goldsmith, CEO, President & Chairman, per Nexqual as of October 23, 2026 at 10:08 UTC.
| CEO, President & Chairman | Mark A. Goldsmith |
|---|---|
| Chief Financial Officer | Jack Anders |
| Chief Operating Officer | Margaret A. Horn |
| Co-Founder & Chairman of Scientific Advisory Board | Martin D. Burke |
| Chief Scientific Officer | Jan Smith |
Major Backers & Investors (RVMD)
Notable institutional backers of Revolution Medicines, Inc. include Farallon Capital Management LLC, FMR, LLC, Baker Bros. Advisors, LP, according to Nexqual as of October 23, 2026 at 10:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 6.32% |
| FMR, LLC | 5.69% |
| Baker Bros. Advisors, LP | 5.34% |
| Jupiter Topco LLC | 5.01% |
| Darwin Global Management, Ltd. | 4.96% |
| Nextech Invest, Ltd. | 3.55% |
| Paradigm Biocapital Advisors LP | 2.97% |
| Growth Fund of America | 1.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.11% |
| BlackRock | 6.39% |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
From Revolution Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- In May 2025, we entered into a collaboration with Iambic Therapeutics (Iambic), pursuant to which Iambic uses its artificial intelligence capabilities to generate customized models through training with our proprietary data.
- Continue to leverage our proprietary tri-complex discovery platform targeting RAS(ON).
- Our success depends in part on our ability and the ability of our collaborators to obtain and maintain proprietary protection for our technology, programs and know-how related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others.
- We also rely on trade secrets, know-how and confidential information relating to our programs to develop and maintain our proprietary position, and seek to protect and maintain the confidentiality of such items to protect aspects of our business that are not amenable to, or that we do not currently consider appropriate for, patent protection.
Partnerships
- In June 2025, we entered into a clinical collaboration with Summit Therapeutics, Inc. (Summit) pursuant to which we are evaluating the safety and efficacy, in multiple solid tumor settings, of our clinical-stage RAS(ON) Inhibitors, including daraxonrasib, elironrasib and zoldonrasib, in combination with Summit's ivonescimab, a PD-1/VEGF bispecific antibody.
- In March 2024, we entered into a collaboration agreement with Aethon Therapeutics, Inc. (Aethon) pursuant to which Aethon is conducting research related to use of novel bispecific antibodies to mount an immune attack directed at the cancer cells targeted by our RAS(ON) Inhibitors (the Aethon Collaboration Agreement).
Legal & Regulatory Risks (Item 1A, quoted)
- The results of preclinical studies and early-stage clinical trials may not be predictive of future results.
- The results of preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of the later-stage clinical trials.
- We and our collaborators are currently developing, and may in the future develop, our product candidates in combination with other therapies, which exposes us to additional risks.
- We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ONC | BeOne Medicines Ltd. | USD 382.27 | ▼ 1.08% |
| RPRX | Royalty Pharma plc | USD 63.75 | ▲ 2.57% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 227.28 | ▲ 0.97% |
| ARGX | argenx SE | USD 875.76 | ▼ 1.61% |
| ROIV | Roivant Sciences Ltd. | USD 37.45 | ▲ 1.77% |
| GMAB | Genmab A/S | USD 40 | ▲ 1.09% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt